Clinical Trials Directory

Trials / Conditions / Ovarian Cancer Recurrent

Ovarian Cancer Recurrent

25 registered clinical trials studyying Ovarian Cancer Recurrent — 11 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
NCT07295132
Asan Medical CenterPhase 2
RecruitingA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
NCT06888921
Compugen LtdPhase 1 / Phase 2
RecruitingA Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
NCT07030907
Outpace Bio, Inc.Phase 1
RecruitingA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447
Merck Sharp & Dohme LLCPhase 1 / Phase 2
RecruitingPegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
NCT06791460
Obstetrics & Gynecology Hospital of Fudan UniversityPhase 2 / Phase 3
RecruitingExploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride
NCT06660511
Second Xiangya Hospital of Central South UniversityEARLY_Phase 1
RecruitingSBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi
NCT05990192
Institute of Cancer Research, United KingdomPhase 2
RecruitingA Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151
Sun Yat-sen University—
Not Yet RecruitingThe Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Rec
NCT06102707
Qilu Hospital of Shandong UniversityN/A
WithdrawnTrial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian
NCT04149145
University of Alabama at BirminghamPhase 1
RecruitingIN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the
NCT06014528
InxMed (Shanghai) Co., Ltd.Phase 2
UnknownMicrotransplantation for Ovarian Cancer
NCT05095558
The Affiliated Hospital of the Chinese Academy of Military Medical SciencesPhase 1 / Phase 2
TerminatedA Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
NCT05001282
Elucida OncologyPhase 1 / Phase 2
CompletedBevacizumab and Tocotrienol in Recurrent Ovarian Cancer
NCT04175470
Vejle HospitalPhase 2
RecruitingSurgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226
Shanghai Gynecologic Oncology GroupPhase 2
Active Not RecruitingSystemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT03734692
Robert EdwardsPhase 1 / Phase 2
UnknownFamitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
NCT03827837
Jiangsu HengRui Medicine Co., Ltd.Phase 2
UnknownHyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
NCT03717610
Uppsala University HospitalN/A
CompletedA Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.
NCT03681548
Ayana Pharma Ltd.,Phase 1
UnknownAdoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT04072263
Leiden University Medical CenterPhase 1 / Phase 2
CompletedDCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian
NCT03657966
SOTIO a.s.Phase 2
TerminatedThe Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian
NCT03162562
CanariaBio Inc.Phase 1
CompletedEP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
NCT01485848
Esperance Pharmaceuticals IncPhase 2
CompletedStudy of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Pacl
NCT01332656
SanofiPhase 2
CompletedA 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late R
NCT01111903
ARCAGY/ GINECO GROUPPhase 1 / Phase 2